All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @eziogecelestine on TikTok · 135s|Watch on TikTok

@eziogecelestine's semaglutide journey, fact-checked

Ezioge Celestine

TikTok creator

172.0K viewsWatch on TikTok

Quick answer

Semaglutide is a GLP-1 receptor agonist that slows gastric emptying and reduces appetite through incretin hormone pathways. Clinical trials show 14.9% average weight loss at 68 weeks when combined with lifestyle interventions, but weight regain occurs rapidly after discontinuation.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @eziogecelestine's semaglutide journey, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@eziogecelestine's semaglutide journey, fact-checked" from Ezioge Celestine. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Semaglutide is a GLP-1 receptor agonist that slows gastric emptying and reduces appetite through incretin hormone pathways.

The reason this review is not generic is the source wording and the canonical claim label "glp1 soo i decided to follow the trend and get on semaglutide f." In this clip, the useful excerpt is: "Soo." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Participants regained two-thirds of lost weight within a year of stopping semaglutide in extension studies
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Semaglutide is a GLP-1 receptor agonist that slows gastric emptying and reduces appetite through incretin hormone pathways.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Semaglutide is a GLP-1 receptor agonist that slows gastric emptying and reduces appetite through incretin hormone pathways. Clinical trials show 14.9% average weight loss at 68 weeks when combined with lifestyle interventions, but weight regain occurs rapidly after discontinuation.
  • STEP 1 trial showed 14.9% average weight loss with 2.4mg semaglutide over 68 weeks versus 2.4% with placebo
  • Participants regained two-thirds of lost weight within a year of stopping semaglutide in extension studies

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • STEP 1 trial showed 14.9% average weight loss with 2.4mg semaglutide over 68 weeks versus 2.4% with placebo
  • Participants regained two-thirds of lost weight within a year of stopping semaglutide in extension studies
  • 74% of trial participants experienced nausea, making gradual dose escalation important for tolerability
  • Clinical effectiveness required 500-calorie daily reduction and 150 minutes of weekly exercise alongside medication
  • Monthly costs range from $1,300-1,400 without insurance coverage, requiring long-term financial planning
  • FDA approval requires BMI ≥30 or BMI ≥27 with weight-related health conditions like diabetes or hypertension
  • Starting dose is typically 0.25mg weekly, increased gradually over 16-20 weeks to maintenance dose of 2.4mg

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What does this video actually claim?

Ezioge Celestine tells her followers she's starting semaglutide for weight loss after struggling with weight her whole life despite being athletic and eating well. She positions it as a "jumpstart" to her weight loss journey at her heaviest weight ever.

The video doesn't make specific medical claims about how the drug works or what results to expect. Instead, it's a personal announcement that she'll document her weekly injections, workouts, and recipes. This approach is actually more responsible than many GLP-1 content creators who promise dramatic results.

Is semaglutide effective for weight loss?

Yes, the clinical evidence is strong. The STEP 1 trial (Wilding et al., NEJM, 2021) found participants lost an average of 14.9% of their body weight over 68 weeks with 2.4mg semaglutide compared to 2.4% with placebo.

But here's what Celestine doesn't mention: this was combined with lifestyle counseling and a reduced-calorie diet. The drug wasn't used alone as a "jumpstart" but as part of comprehensive lifestyle changes. The STEP trials required participants to reduce their caloric intake by 500 calories daily and exercise for at least 150 minutes weekly.

About 86% of participants in STEP 1 lost at least 5% of their body weight, and 69% lost at least 10%. These aren't small effects, but they required consistent lifestyle modifications alongside the medication.

What's missing from this approach?

Celestine frames semaglutide as a way to "jumpstart" her journey, but this misunderstands how GLP-1 medications work. They're not temporary kickstarters but long-term treatments that require ongoing use to maintain weight loss.

The STEP 1 extension study (Rubino et al., Diabetes Obes Metab, 2022) showed participants regained two-thirds of their lost weight within a year of stopping semaglutide. The medication works by slowing gastric emptying and reducing appetite through GLP-1 receptor activation, but these effects reverse when you stop taking it.

She also doesn't mention the common side effects. In clinical trials, 74% of participants experienced nausea, 38% had vomiting, and 30% had diarrhea. Most people can manage these by starting with 0.25mg weekly and slowly increasing the dose over 16-20 weeks.

What should you actually know?

Celestine gets credit for not overpromising results or making medical claims about the drug. But her "jumpstart" framing could mislead people about how GLP-1 medications actually work.

The real story is that semaglutide is highly effective for weight loss when combined with lifestyle changes and used long-term. The average cost is $1,300-1,400 monthly without insurance, making it a significant financial commitment. Most insurance plans require documentation of previous weight loss attempts and specific BMI thresholds.

If you're considering semaglutide, expect it to be part of your routine for years, not months. The clinical trials that proved its effectiveness involved long-term use with ongoing dietary and exercise modifications. There's no evidence it works as a short-term jumpstart to other weight loss methods.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Ezioge Celestine · TikTok creator

172.0K views on this video

Soo.. I decided to follow the trend and get on Semaglutide for weight loss💉. My weight has always been a struggle my entire life. I was always the heavier one in the group, despite being in sports, w

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about step 1 trial showed 14.9% average weight loss with 2.4mg?

STEP 1 trial showed 14.9% average weight loss with 2.4mg semaglutide over 68 weeks versus 2.4% with placebo

What does the video say about participants regained two-thirds of lost weight within a year of?

Participants regained two-thirds of lost weight within a year of stopping semaglutide in extension studies

What does the video say about 74% of trial participants experienced nausea, making gradual dose escalation?

74% of trial participants experienced nausea, making gradual dose escalation important for tolerability

What does the video say about clinical effectiveness required 500-calorie daily reduction?

Clinical effectiveness required 500-calorie daily reduction and 150 minutes of weekly exercise alongside medication

What does the video say about monthly costs range from $1,300-1,400 without insurance coverage, requiring long-term?

Monthly costs range from $1,300-1,400 without insurance coverage, requiring long-term financial planning

What does the video say about fda approval requires bmi ≥30?

FDA approval requires BMI ≥30 or BMI ≥27 with weight-related health conditions like diabetes or hypertension

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Ezioge Celestine, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.